|Full HTA submission received from Applicant
|As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant
|Full submission received from Applicant